Pediatrix Medical Group, Inc. (NYSE:MD) Receives $16.25 Consensus Target Price from Brokerages

Pediatrix Medical Group, Inc. (NYSE:MD) has been assigned an average recommendation of “Hold” from the six ratings firms that are covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $16.25.

Several equities analysts recently commented on the stock. UBS Group increased their target price on shares of Pediatrix Medical Group from $10.50 to $16.50 and gave the company a “neutral” rating in a report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Pediatrix Medical Group from $9.00 to $15.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Macquarie began coverage on shares of Pediatrix Medical Group in a research report on Monday, December 16th. They set an “outperform” rating and a $18.00 price target for the company. StockNews.com raised shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating in a research report on Wednesday, January 22nd. Finally, Jefferies Financial Group increased their price target on shares of Pediatrix Medical Group from $14.00 to $18.00 and gave the company a “buy” rating in a research report on Tuesday, November 5th.

Insider Buying and Selling

In other Pediatrix Medical Group news, Director Mark S. Ordan sold 27,600 shares of the business’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $15.35, for a total value of $423,660.00. Following the completion of the transaction, the director now owns 138,683 shares of the company’s stock, valued at approximately $2,128,784.05. The trade was a 16.60 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Mary Ann E. Moore sold 8,108 shares of the firm’s stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $16.00, for a total transaction of $129,728.00. Following the sale, the executive vice president now directly owns 135,810 shares in the company, valued at approximately $2,172,960. The trade was a 5.63 % decrease in their position. The disclosure for this sale can be found here. 2.00% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. State Street Corp increased its holdings in Pediatrix Medical Group by 1.4% during the third quarter. State Street Corp now owns 3,540,791 shares of the company’s stock valued at $41,038,000 after buying an additional 50,597 shares during the last quarter. Nordea Investment Management AB raised its holdings in Pediatrix Medical Group by 51.6% in the 4th quarter. Nordea Investment Management AB now owns 263,633 shares of the company’s stock worth $3,504,000 after purchasing an additional 89,739 shares during the period. Barclays PLC lifted its position in Pediatrix Medical Group by 302.9% during the third quarter. Barclays PLC now owns 142,087 shares of the company’s stock valued at $1,646,000 after purchasing an additional 106,817 shares in the last quarter. Franklin Resources Inc. bought a new stake in Pediatrix Medical Group during the third quarter valued at about $598,000. Finally, Principal Financial Group Inc. increased its position in Pediatrix Medical Group by 14.1% in the third quarter. Principal Financial Group Inc. now owns 513,618 shares of the company’s stock worth $5,953,000 after buying an additional 63,581 shares in the last quarter. 97.71% of the stock is owned by hedge funds and other institutional investors.

Pediatrix Medical Group Price Performance

Shares of NYSE:MD opened at $14.22 on Friday. The company’s fifty day moving average price is $13.99 and its 200-day moving average price is $12.22. The firm has a market capitalization of $1.22 billion, a price-to-earnings ratio of -4.65, a PEG ratio of 1.42 and a beta of 1.58. Pediatrix Medical Group has a one year low of $6.62 and a one year high of $16.41. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.42 and a quick ratio of 1.42.

Pediatrix Medical Group (NYSE:MD) last released its earnings results on Friday, November 1st. The company reported $0.44 EPS for the quarter, beating the consensus estimate of $0.37 by $0.07. Pediatrix Medical Group had a negative net margin of 12.65% and a positive return on equity of 12.79%. The company had revenue of $511.20 million for the quarter, compared to analyst estimates of $498.87 million. During the same quarter last year, the firm earned $0.29 EPS. The firm’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities research analysts anticipate that Pediatrix Medical Group will post 1.26 earnings per share for the current fiscal year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.